Your browser doesn't support javascript.
loading
Protocol modifications reduce risk of delayed pericardial effusions after vein of Marshall ethanol infusion: follow-up from the Maine experience.
Leyton-Mange, Jordan S; Haskell, Amanda D; Tandon, Kunal; Corsello, Andrew C; Black-Maier, Eric; Sze, Edward Y; Sesselberg, Henry W.
Affiliation
  • Leyton-Mange JS; Department of Cardiology, Maine Medical Center, Portland, ME, 04102, USA. jordan.leyton-mange@mainehealth.org.
  • Haskell AD; Maine Medical Partners MaineHealth Cardiology, 96 Campus Drive, Scarborough, ME, 04074, USA. jordan.leyton-mange@mainehealth.org.
  • Tandon K; Department of Cardiology, Maine Medical Center, Portland, ME, 04102, USA.
  • Corsello AC; Department of Cardiology, Maine Medical Center, Portland, ME, 04102, USA.
  • Black-Maier E; Maine Medical Partners MaineHealth Cardiology, 96 Campus Drive, Scarborough, ME, 04074, USA.
  • Sze EY; Department of Cardiology, Maine Medical Center, Portland, ME, 04102, USA.
  • Sesselberg HW; Maine Medical Partners MaineHealth Cardiology, 96 Campus Drive, Scarborough, ME, 04074, USA.
Article in En | MEDLINE | ID: mdl-38914901
ABSTRACT

BACKGROUND:

While ethanol infusion into the vein of Marshall (VOM) as an adjunct to atrial fibrillation ablation has shown promise, adoption has been limited by the technical expertise required, unclear antiarrhythmic mechanism, and complication risk. Delayed pericardial effusions have been associated with ethanol infusion into the VOM in prior studies. Very little is known about how the procedural approach itself can impact the risk of delayed effusions. We sought to understand the incidence and influence of procedural technique on complications including delayed pericardial effusions from VOM ethanol infusion at a large single medical center.

METHODS:

A total of 275 atrial ablation cases wherein VOM ethanol infusion was attempted were identified from the time of the program's inception in 2019 at Maine Medical Center (Portland, ME) until October of 2023. Cases were classified into phase I cases (early experience) and phase II cases (later experience) based upon temporal programmatic changes in the ethanol dose and infusion rate as well as the use of routine VOM venography. Procedural details and complications were adjudicated from the medical record.

RESULTS:

The overall VOM ethanol infusion success was 91.4%. Nine complications (3.3%) occurred in eight patients (2.9% of patients). These were more frequent in phase I (5.8%) compared to phase II (1.3%, p = 0.047). This difference was driven by a difference in delayed presentations of tamponade, which occurred in four patients in phase I (3.3%) and in no patients in phase II (0%, p = 0.037). Twelve-month estimated atrial arrhythmia freedom did not differ between groups (73.8% phase I vs 70.4% phase II, p = 0.24).

CONCLUSION:

In our single-center experience, adjustments to the procedural approach with lower ethanol infusion rate and dosage, combined with utilizing selective VOM venography, associated with a lowering of complication rates and in particular, delayed pericardial tamponade.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Interv Card Electrophysiol Journal subject: CARDIOLOGIA Year: 2024 Document type: Article Affiliation country: United States Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Interv Card Electrophysiol Journal subject: CARDIOLOGIA Year: 2024 Document type: Article Affiliation country: United States Country of publication: Netherlands